Guillain-Barré syndrome
DOI:
https://doi.org/10.59059/mutiara.v3i3.2334Keywords:
Autoimmune, Guillain-Barré Syndrome, IVIGAbstract
Guillain-Barré Syndrome (GBS) is a serious but rare post-infectious immune-mediated neuropathy. This disease is caused by autoimmune damage to nerves in the peripheral nervous system causing symptoms such as numbness, tingling, and weakness that can progress to paralysis. The incidence of GBS is 0.42 cases per 100,000 people. The highest incidence occurs in adolescents and the elderly at the age of 50 years. While in children, cases with Acute Flaccid Paralysis occur in 25.9% - 50% of children. So the incidence of GBS in children is 0.34 cases per 100,000 children. If it attacks children, they will experience progressive motor development disorders, and can even cause death. The most effective therapy is generally intravenous immunoglobulin (IVIG). In general, the outcome of GBS is more favorable in children than in adults; however, the recovery period is long, often weeks to months.
References
Barroso, E., Tuta-Quintero, E., Olivella, J., Aragón, C., Vásquez, L., Acosta, L., et al. (2022). Guillain Barré syndrome in the paediatric population: Consequence of active infection or long Covid? Revista Colombiana de Reumatología, 29(4), 335–346.
DiFazio, M. P., & Jallo, G. I. (2019). Pediatric Guillain-Barre Syndrome. Medscape, 1–15.
Hughes, R. A. C., & Cornblath, D. R. (2005). Guillain-Barré syndrome. The Lancet, 366(9497), 1653–1666. https://doi.org/10.1016/S0140-6736(05)67665-9
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., et al. (2019). Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology, 15(11), 671–683. https://doi.org/10.1038/s41582-019-0250-9
Luthfiyani, L., & Widodo, A. (2021). Activity prone position untuk respirasi pada anak Guillain Barre Syndrome. FISIO MU: Physiotherapy Evidences, 2(1), 54–58.
McGrogan, A., Madle, G. C., Seaman, H. E., & de Vries, C. S. (2009). The epidemiology of Guillain-Barré syndrome worldwide: A systematic literature review. Neuroepidemiology, 32(2), 150–163. https://doi.org/10.1159/000184748
Nasiri, J., Ghazavi, M., Yaghini, O., & Chaldavi, M. (2018). Clinical features and outcome of Guillain-Barré Syndrome in children. Iranian Journal of Child Neurology.
Nguyen, T. P., & Taylor, R. S. (2024). Guillain-Barre Syndrome. StatPearls Publishing, 1–11.
Ropper, A. H. (1992). The Guillain-Barré syndrome. New England Journal of Medicine, 326(17), 1130–1136. https://doi.org/10.1056/NEJM199204233261706
Salehiomran, M. R., Nikkhah, A., & Mahdavi, M. (2016). Prognosis of Guillain-Barré Syndrome in children. Iranian Journal of Child Neurology. Retrieved from http://kstudy.com/journal/thesis_name.asp?tname=2002&key=3183676
Sejvar, J. J., Baughman, A. L., Wise, M., & Morgan, O. W. (2011). Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology, 36(2), 123–133. https://doi.org/10.1159/000324710
Shibeshi, M. S., Mengesha, A. A., & Gari, K. T. (2023). Pediatric Guillain–Barré Syndrome in a resource-limited setting: Clinical features, diagnostic and management challenges, and hospital outcome. Pediatric Health, Medicine and Therapeutics, 14, 107–115.
van Doorn, P. A., Van den Bergh, P. Y. K., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Attarian, S., et al. (2023). European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain–Barré syndrome. Journal of the Peripheral Nervous System, 28(4), 535–563.
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016). Guillain-Barré syndrome. The Lancet, 388(10045), 717–727. https://doi.org/10.1016/S0140-6736(16)00339-1
Yuki, N., & Hartung, H. P. (2012). Guillain-Barré syndrome. New England Journal of Medicine, 366(24), 2294–2304. https://doi.org/10.1056/NEJMra1114525
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mutiara : Jurnal Penelitian dan Karya Ilmiah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
